Vator Securities hosted a Product Launch Insight event for Xlucane together with German STADA Arzneimittel and Xbrane Biopharma yesterday, 11 April 2019.
EVP Global Communications Frank Staud and Director Global Biosimilars Patrick Schlebrowski presented STADAS Biosimilar strategy, market expectations, pipeline and a more detailed look at Xlucane (co-dev by Xbrane/STADA) product launch.
Presenting at the event were Patrick Schlebrowski and Frank Staud from STADA together with Xbrane’s Chairman Anders Tullgren and Martin Åmark, CEO.